Genotypes in matrix metalloproteinase 9 are a risk factor for COPD

A growing body of evidence indicates that matrix metalloproteinases (MMPs) play a role in the pathogenesis of COPD. Therefore, we conducted a candidate gene association study of 4 promoter polymorphisms that are known to modify expression levels of the MMP-1, MMP-2, and MMP-9 genes and a Gln279Arg polymorphism in exon 6 of MMP-9 that modifies the substrate-binding region. We examined the association of each variant and haplotypes in 385 male veterans with greater than 20 pack-years of cigarette smoking whose COPD status was characterized using spirometry. The association of these polymorphisms was also examined with decline of pulmonary function in a subset of participants. Only the 279Arg variant was more common in participants with COPD and the homozygous variant was associated with a 3-fold increased risk for COPD. In the haplotype analysis, the haplotype comprising the 249Arg and the CA promoter polymorphism within the MMP-9 gene was associated with risk, suggesting that either 279Arg or a linked variant on this haplotype underlies the association. No association of this polymorphism was found with decline in pulmonary function. These studies show that variants of the MMP-9 gene are associated with COPD in this cohort of veterans.

[1]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[2]  Y. Chu,et al.  Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression. , 2003, Biochemical and biophysical research communications.

[3]  M. Oka,et al.  Association of functional polymorphisms of matrix metalloproteinase (MMP)‐1 and MMP‐3 genes with colorectal cancer , 2002, International journal of cancer.

[4]  W. Tan,et al.  Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. , 2002, Cancer research.

[5]  N. Anthonisen,et al.  The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. , 2002, Human molecular genetics.

[6]  A. Sandford,et al.  Genetic risk factors for chronic obstructive pulmonary disease. , 2002, Clinics in chest medicine.

[7]  Hidetoshi Nakamura,et al.  Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. , 2001, Biochemical and biophysical research communications.

[8]  C. ZAPATA,et al.  Sampling variance and distribution of the D′ measure of overall gametic disequilibrium between multiallelic loci , 2001, Annals of human genetics.

[9]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[10]  D. Greaves,et al.  Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene , 2001, The Journal of Biological Chemistry.

[11]  J. D’Armiento,et al.  Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. , 2001, American journal of respiratory and critical care medicine.

[12]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[13]  K. Chung,et al.  Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. , 2000, American journal of respiratory and critical care medicine.

[14]  M. Gaxiola,et al.  Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. , 2000, Chest.

[15]  H Yonas,et al.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. , 1999, Stroke.

[16]  A. Henney,et al.  Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1 , 1999, Human Genetics.

[17]  Y. Sasaguri,et al.  Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene , 1999, FEBS letters.

[18]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[19]  J. Gusella,et al.  A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. , 1998, Cancer research.

[20]  J. Bousquet,et al.  Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. , 1998, American journal of respiratory and critical care medicine.

[21]  Y. Konttinen,et al.  Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[22]  S. Shapiro,et al.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.

[23]  M Raymond,et al.  Testing differentiation in diploid populations. , 1996, Genetics.

[24]  Laurent Excoffier,et al.  Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm , 1996, Heredity.

[25]  L. Excoffier,et al.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.

[26]  B. Henderson,et al.  Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. , 1995, American journal of epidemiology.

[27]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[28]  Y. Okada,et al.  Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema , 1992, Cell.

[29]  E. Thompson,et al.  Performing the exact test of Hardy-Weinberg proportion for multiple alleles. , 1992, Biometrics.

[30]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[31]  L. Matrisian,et al.  Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the "cysteine switch". , 1991, The Journal of biological chemistry.

[32]  G. Man,et al.  Tracheal mucus rheology in patients undergoing diagnostic bronchoscopy. Interrelations with smoking and cancer. , 1990, The American review of respiratory disease.

[33]  B. Cohen.  COMMON FAMILIAL COMPONENT IN LUNG CANCER AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE , 1978, The Lancet.

[34]  R. Lewontin.  The Interaction of Selection and Linkage. I. General Considerations; Heterotic Models. , 1964, Genetics.

[35]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[36]  W. Pryor,et al.  Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. , 1994, The American journal of physiology.

[37]  J. Lammers.  Obstructive lung disease. , 1990, The Medical clinics of North America.

[38]  M. Ashburner.  A Laboratory manual , 1989 .

[39]  C. A. Thomas,et al.  Molecular cloning. , 1977, Advances in pathobiology.

[40]  C. Laurell,et al.  Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency. , 1967, Scandinavian journal of clinical and laboratory investigation.

[41]  C. Laurell,et al.  Obstructive Lung Disease and Trypsin Inhibitors in α1-Antitrypsin Deficiency , 1967 .